US7235551B2
(en)
*
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
CN100457118C
(zh)
|
2000-04-13 |
2009-02-04 |
法玛塞特有限公司 |
用于治疗肝炎病毒感染的3′-或2′-羟甲基取代的核苷衍生物
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
JP5230052B2
(ja)
|
2000-05-26 |
2013-07-10 |
イデニクス(ケイマン)リミテツド |
フラビウイルスおよびペスチウイルス治療のための方法および組成物
|
JP4524072B2
(ja)
|
2000-10-23 |
2010-08-11 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
新規化合物
|
KR100828453B1
(ko)
|
2001-01-22 |
2008-05-13 |
머크 앤드 캄파니 인코포레이티드 |
Rna 의존성 rna 바이러스 폴리머라제의억제제로서의 뉴클레오시드 유도체
|
US8481712B2
(en)
|
2001-01-22 |
2013-07-09 |
Merck Sharp & Dohme Corp. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
JP2005504087A
(ja)
*
|
2001-09-28 |
2005-02-10 |
イデニクス(ケイマン)リミテツド |
4’が修飾されたヌクレオシドを使用するc型肝炎ウイルス治療のための方法および組成物
|
US7321033B2
(en)
*
|
2001-11-27 |
2008-01-22 |
Anadys Pharmaceuticals, Inc. |
3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
|
US7217815B2
(en)
*
|
2002-01-17 |
2007-05-15 |
Valeant Pharmaceuticals North America |
2-beta -modified-6-substituted adenosine analogs and their use as antiviral agents
|
WO2003088972A1
(en)
*
|
2002-04-19 |
2003-10-30 |
Smithkline Beecham Corporation |
Novel compounds
|
US20070004669A1
(en)
*
|
2002-06-21 |
2007-01-04 |
Carroll Steven S |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
WO2004003138A2
(en)
*
|
2002-06-27 |
2004-01-08 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
NZ537662A
(en)
*
|
2002-06-28 |
2007-10-26 |
Idenix Cayman Ltd |
2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
CN103275159A
(zh)
*
|
2002-06-28 |
2013-09-04 |
埃迪尼克斯医药公司 |
用于治疗黄病毒感染的修饰的2’和3’-核苷前药
|
US7608600B2
(en)
*
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
WO2004002422A2
(en)
*
|
2002-06-28 |
2004-01-08 |
Idenix (Cayman) Limited |
2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
CA2490666A1
(en)
*
|
2002-07-16 |
2004-01-22 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
WO2004009020A2
(en)
*
|
2002-07-24 |
2004-01-29 |
Merck & Co., Inc. |
Pyrrolopyrimidine thionucleoside analogs as antivirals
|
AU2003257157C1
(en)
|
2002-08-01 |
2010-03-18 |
Pharmasset Inc. |
Compounds with the bicyclo[4.2.1] nonane system for the treatment of Flaviviridae infections
|
JP2006505537A
(ja)
*
|
2002-09-30 |
2006-02-16 |
ジェネラブス テクノロジーズ,インコーポレイテッド |
C型肝炎ウイルスの感染を治療するためのヌクレオシド誘導体
|
SI1576138T1
(sl)
|
2002-11-15 |
2017-07-31 |
Idenix Pharmaceuticals Llc |
2'-metil nukleozidi v kombinaciji z interferon in flaviviridae mutacijo
|
GB0228545D0
(en)
*
|
2002-12-06 |
2003-01-15 |
Glaxo Group Ltd |
Novel compounds
|
AU2003300901A1
(en)
*
|
2002-12-12 |
2004-06-30 |
Idenix (Cayman) Limited |
Process for the production of 2'-branched nucleosides
|
BR0316868A
(pt)
*
|
2002-12-23 |
2005-10-25 |
Idenix Cayman Ltd |
Processo para a produção de pró-medicamentos de nucleosìdeo-3'
|
US7799908B2
(en)
*
|
2003-01-15 |
2010-09-21 |
Valeant Pharmaceuticals North America |
Synthesis and use of 2′-substituted-N6 -modified nucleosides
|
EP1611125A1
(en)
*
|
2003-02-07 |
2006-01-04 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl substituted pyrolls useful as inhibitors of protein kinases
|
WO2004098590A1
(en)
*
|
2003-05-02 |
2004-11-18 |
Elan Pharmaceuticals, Inc. |
4-bromo-5- (2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-(aminocarbonyl) eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
|
US7417152B2
(en)
*
|
2003-05-02 |
2008-08-26 |
Elan Pharmaceuticals, Inc. |
4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases
|
EP1635821B1
(en)
*
|
2003-05-02 |
2009-07-08 |
Elan Pharmaceuticals, Inc. |
4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl)amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
|
EP1658302B1
(en)
*
|
2003-07-25 |
2010-08-25 |
IDENIX Pharmaceuticals, Inc. |
Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
|
BRPI0414045A
(pt)
*
|
2003-09-05 |
2006-10-24 |
Anadys Pharmaceuticals Inc |
administração de ligantes de tlr7 e pró-medicamentos dos mesmos para tratamento de infecção por vìrus de hepatite c
|
US20050182252A1
(en)
*
|
2004-02-13 |
2005-08-18 |
Reddy K. R. |
Novel 2'-C-methyl nucleoside derivatives
|
CN103319464A
(zh)
|
2004-02-20 |
2013-09-25 |
贝林格尔.英格海姆国际有限公司 |
病毒聚合酶抑制剂
|
SG10201501376XA
(en)
|
2004-03-04 |
2015-04-29 |
Leuven K U Res & Dev |
Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
|
US7534767B2
(en)
|
2004-06-15 |
2009-05-19 |
Merck & Co., Inc. |
C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
|
EP1912643A2
(en)
*
|
2004-06-23 |
2008-04-23 |
Idenix (Cayman) Limited |
5-aza-7-deazapurine derivatives for treating infections with flaviviridae
|
CA2571079A1
(en)
*
|
2004-06-24 |
2006-02-02 |
Merck & Co., Inc. |
Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
|
CN101072570A
(zh)
*
|
2004-09-24 |
2007-11-14 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒、瘟病毒和肝炎病毒的方法和组合物
|
WO2006050161A2
(en)
|
2004-10-29 |
2006-05-11 |
Biocryst Pharmaceuticals, Inc. |
Therapeutic furopyrimidines and thienopyrimidines
|
AR052995A1
(es)
|
2004-12-17 |
2007-04-18 |
Anadys Pharmaceuticals Inc |
Compuestos de 3h-oxazolo y 3h-tiazolo[4, 5 - d]pirimidin-2-ona3, 5-disustituidos y 3, 5, 7-trisustituidos con actividad inmunomoduladora, sus profarmacos, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de enfermedades de origen viral
|
JP5002851B2
(ja)
*
|
2005-01-20 |
2012-08-15 |
独立行政法人理化学研究所 |
イミダゾピリジン誘導体
|
WO2007144686A1
(en)
*
|
2005-03-09 |
2007-12-21 |
Idenix (Cayman) Limited |
Nucleosides with non-natural bases as anti-viral agents
|
PE20061193A1
(es)
*
|
2005-03-25 |
2006-12-02 |
Glaxo Group Ltd |
DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
|
AR053346A1
(es)
|
2005-03-25 |
2007-05-02 |
Glaxo Group Ltd |
Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
|
US20090137550A1
(en)
*
|
2005-03-25 |
2009-05-28 |
Glaxo Group Limited |
Novel Compounds
|
CA2603163A1
(en)
*
|
2005-03-25 |
2006-10-05 |
Glaxo Group Limited |
Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
|
JP5107228B2
(ja)
*
|
2005-03-29 |
2012-12-26 |
バイオクライスト ファーマシューティカルズ, インコーポレイテッド |
C型肝炎治療
|
JP4705164B2
(ja)
*
|
2005-05-02 |
2011-06-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Hcvns3プロテアーゼ阻害剤
|
EP2546246A3
(en)
|
2005-05-13 |
2013-04-24 |
Virochem Pharma Inc. |
Compounds and methods for the treatment or prevention of flavivirus infections
|
AR057456A1
(es)
|
2005-07-20 |
2007-12-05 |
Merck & Co Inc |
Inhibidores de la proteasa ns3 del vhc
|
NZ565269A
(en)
*
|
2005-08-01 |
2010-03-26 |
Merck & Co Inc |
Macrocyclic peptides as HCV NS3 protease inhibitors
|
US7632821B2
(en)
*
|
2005-08-09 |
2009-12-15 |
Merck & Co., Inc. |
Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection
|
EA201200669A1
(ru)
|
2005-10-07 |
2012-11-30 |
Экселиксис, Инк. |
ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
|
KR20140105621A
(ko)
|
2005-10-07 |
2014-09-01 |
엑셀리시스, 인코포레이티드 |
PI3Kα의 피리도피리미디논 억제제
|
ES2345904T3
(es)
|
2005-11-21 |
2010-10-05 |
Anadys Pharmaceuticals, Inc. |
Proceso para preparar 5-amino-3h-tiazolo(4,5-d)pirimidin-2-ona.
|
BRPI0619261A2
(pt)
*
|
2005-11-30 |
2011-09-27 |
Inotek Pharmaceuticals Corp |
derivados de purina e métodos de uso desses
|
CA2634749C
(en)
*
|
2005-12-23 |
2014-08-19 |
Idenix Pharmaceuticals, Inc. |
Process for preparing a synthetic intermediate for preparation of branched nucleosides
|
KR20080110816A
(ko)
*
|
2006-03-23 |
2008-12-19 |
이노텍 파마슈티컬스 코포레이션 |
퓨린 화합물 및 이의 사용 방법
|
GB0609492D0
(en)
*
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
TWI418561B
(zh)
*
|
2006-06-22 |
2013-12-11 |
Anadys Pharmaceuticals Inc |
5-胺基-3-(3’-去氧-β-D-核糖呋喃糖基(ribofuranosyl))-噻唑并〔4,5-d〕嘧啶-2,7-二酮之前藥
|
GB0612423D0
(en)
*
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
EP2040712B1
(en)
|
2006-07-18 |
2011-03-02 |
Anadys Pharmaceuticals, Inc. |
Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
|
MY146420A
(en)
|
2006-09-15 |
2012-08-15 |
Pfizer Prod Inc |
Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
|
US7968556B2
(en)
|
2006-10-19 |
2011-06-28 |
Signal Pharmaceuticals, Llc |
Heteroaryl compounds, compositions thereof, and methods of treatment therewith
|
CA2667266C
(en)
|
2006-10-24 |
2015-11-24 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
WO2008051475A2
(en)
|
2006-10-24 |
2008-05-02 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
AU2007309546A1
(en)
|
2006-10-24 |
2008-05-02 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
HCV NS3 protease inhibitors
|
AU2007318165B2
(en)
|
2006-10-27 |
2011-11-17 |
Msd Italia S.R.L. |
HCV NS3 protease inhibitors
|
CA2667032A1
(en)
*
|
2006-10-27 |
2008-05-15 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
GB0625349D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
GB0625345D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
AU2007335962B2
(en)
|
2006-12-20 |
2012-09-06 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Antiviral indoles
|
US7951789B2
(en)
|
2006-12-28 |
2011-05-31 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US8071568B2
(en)
|
2007-01-05 |
2011-12-06 |
Merck Sharp & Dohme Corp. |
Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
|
TW200838550A
(en)
|
2007-02-09 |
2008-10-01 |
Novartis Ag |
Organic compounds
|
GB0709791D0
(en)
*
|
2007-05-22 |
2007-06-27 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
CA2695330C
(en)
*
|
2007-07-12 |
2017-06-13 |
University Of South Florida |
Inhibitors of akt/pkb with anti-tumor activity
|
AU2008277440A1
(en)
*
|
2007-07-17 |
2009-01-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Macrocyclic indole derivatives for the treatment of hepatitis C infections
|
AU2008277377B2
(en)
*
|
2007-07-19 |
2013-08-01 |
Msd Italia S.R.L. |
Macrocyclic compounds as antiviral agents
|
HUE038946T2
(hu)
|
2008-04-23 |
2018-12-28 |
Gilead Sciences Inc |
1'-szubsztituált carba-nukleozid analógok antivirális kezelésre
|
CA2720850A1
(en)
*
|
2008-04-28 |
2009-11-05 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
KR20110065440A
(ko)
*
|
2008-07-02 |
2011-06-15 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
바이러스 감염의 치료를 위한 화합물 및 제약 조성물
|
EP2313102A2
(en)
|
2008-07-03 |
2011-04-27 |
Biota Scientific Management |
Bycyclic nucleosides and nucleotides as therapeutic agents
|
PT2310095E
(pt)
|
2008-07-22 |
2012-11-16 |
Angeletti P Ist Richerche Bio |
Compostos de quinoxalina macrocílicos como inibidores da protease ns3 do hcv
|
UA103195C2
(uk)
|
2008-08-11 |
2013-09-25 |
Глаксосмитклайн Ллк |
Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
|
GB0815968D0
(en)
*
|
2008-09-03 |
2008-10-08 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
US8101622B2
(en)
|
2008-09-30 |
2012-01-24 |
Exelixis, Inc. |
Pyridopyrimidinone inhibitors of PI3Kα and mTOR
|
WO2010082050A1
(en)
|
2009-01-16 |
2010-07-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
|
GB0900914D0
(en)
|
2009-01-20 |
2009-03-04 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
AU2010221419B2
(en)
|
2009-03-02 |
2015-10-01 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid chemical modifications
|
EA201190178A1
(ru)
*
|
2009-03-20 |
2012-06-29 |
Алиос Биофарма, Инк. |
Замещённые нуклеозидные и нуклеотидные аналоги
|
WO2010114900A1
(en)
|
2009-03-31 |
2010-10-07 |
Arqule, Inc. |
Substituted indolo-piperidine compounds
|
NZ700583A
(en)
*
|
2009-04-22 |
2016-04-29 |
Acad Of Science Czech Republic |
Novel 7-deazapurine nucleosides for therapeutic uses
|
TWI490219B
(zh)
|
2009-06-29 |
2015-07-01 |
Incyte Corp |
作為pi3k抑制劑之嘧啶酮
|
EP2459582B1
(en)
|
2009-07-30 |
2015-05-27 |
Merck Sharp & Dohme Corp. |
Hepatitis c virus ns3 protease inhibitors
|
EP2459211A1
(en)
|
2009-07-31 |
2012-06-06 |
Medtronic, Inc. |
Continuous subcutaneous administration of interferon- to hepatitis c infected patients
|
MX2012003126A
(es)
|
2009-09-21 |
2012-06-19 |
Gilead Sciences Inc |
Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos.
|
CN102686599B
(zh)
*
|
2009-09-29 |
2016-10-05 |
杨森产品有限公司 |
核苷的氨基磷酸酯衍生物
|
KR101903925B1
(ko)
|
2009-10-26 |
2018-10-02 |
시그날 파마소티칼 엘엘씨 |
헤테로아릴 화합물의 합성 및 정제 방법
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
TW201130842A
(en)
*
|
2009-12-18 |
2011-09-16 |
Incyte Corp |
Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
|
EP2528930B1
(en)
*
|
2010-01-28 |
2013-10-30 |
F.Hoffmann-La Roche Ag |
4'-azido-nucleosides as anti-hcv compounds
|
AR080151A1
(es)
|
2010-02-09 |
2012-03-14 |
Exelixis Inc |
Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
|
WO2011123621A2
(en)
|
2010-04-01 |
2011-10-06 |
Alnylam Pharmaceuticals Inc. |
2' and 5' modified monomers and oligonucleotides
|
TWI515000B
(zh)
|
2010-04-01 |
2016-01-01 |
伊迪尼克製藥公司 |
用於治療病毒感染之化合物及醫藥組合物
|
CA2796311A1
(en)
|
2010-04-14 |
2011-10-20 |
Incyte Corporation |
Fused derivatives as pi3k.delta. inhibitors
|
WO2011163195A1
(en)
|
2010-06-21 |
2011-12-29 |
Incyte Corporation |
Fused pyrrole derivatives as pi3k inhibitors
|
CA2804375C
(en)
|
2010-07-19 |
2018-08-21 |
Gilead Sciences, Inc. |
Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
|
PL2595980T3
(pl)
|
2010-07-22 |
2015-03-31 |
Gilead Sciences Inc |
Sposoby i związki do leczenia infekcji wirusowych Paramyxoviridae
|
US8871737B2
(en)
|
2010-09-22 |
2014-10-28 |
Alios Biopharma, Inc. |
Substituted nucleotide analogs
|
US20120295911A1
(en)
|
2010-11-29 |
2012-11-22 |
Galleon Pharmaceuticals, Inc. |
Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
|
AU2011336764B2
(en)
|
2010-11-29 |
2017-02-23 |
Galleon Pharmaceuticals, Inc. |
Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
|
TW201249844A
(en)
|
2010-12-20 |
2012-12-16 |
Incyte Corp |
N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
|
WO2012092484A2
(en)
|
2010-12-29 |
2012-07-05 |
Inhibitex, Inc. |
Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
|
WO2012125629A1
(en)
|
2011-03-14 |
2012-09-20 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
|
US9126948B2
(en)
|
2011-03-25 |
2015-09-08 |
Incyte Holdings Corporation |
Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
|
US20140065223A1
(en)
*
|
2011-03-31 |
2014-03-06 |
Jeanette Libera-Koerner |
Perfluorinated compounds for the non-viral transfer of nucleic acids
|
CA2843324A1
(en)
|
2011-03-31 |
2012-11-15 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2012142085A1
(en)
|
2011-04-13 |
2012-10-18 |
Merck Sharp & Dohme Corp. |
2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
EP2697242B1
(en)
|
2011-04-13 |
2018-10-03 |
Merck Sharp & Dohme Corp. |
2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
CA2832449A1
(en)
|
2011-04-13 |
2012-10-18 |
Vinay GIRIJAVALLABHAN |
2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
WO2013009735A1
(en)
|
2011-07-13 |
2013-01-17 |
Merck Sharp & Dohme Corp. |
5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
US9408863B2
(en)
|
2011-07-13 |
2016-08-09 |
Merck Sharp & Dohme Corp. |
5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
|
WO2013014052A1
(en)
|
2011-07-22 |
2013-01-31 |
Glaxosmithkline Llc |
Composition
|
EP2751109B1
(en)
|
2011-09-02 |
2016-11-30 |
Incyte Holdings Corporation |
Heterocyclylamines as pi3k inhibitors
|
EP3659599B1
(en)
|
2011-10-19 |
2022-12-21 |
Signal Pharmaceuticals, LLC |
1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one for use in the treatment of glioblastoma multiforme
|
EP2780026B1
(en)
|
2011-11-15 |
2019-10-23 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
MX363034B
(es)
|
2011-12-02 |
2019-03-06 |
Signal Pharm Llc |
Composiciones farmaceuticas de 7-(6-(2-hidroxipropan-2-il)piridin- 3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b]pi razin-2(1h)-ona, una forma solida de las mismas y metodos de su uso.
|
AU2012358804B2
(en)
|
2011-12-22 |
2018-04-19 |
Alios Biopharma, Inc. |
Substituted phosphorothioate nucleotide analogs
|
CN104271159B
(zh)
|
2012-02-24 |
2017-11-28 |
西格诺药品有限公司 |
利用tor激酶抑制剂联合治疗来治疗非小细胞肺癌的方法
|
US8916538B2
(en)
|
2012-03-21 |
2014-12-23 |
Vertex Pharmaceuticals Incorporated |
Solid forms of a thiophosphoramidate nucleotide prodrug
|
EP2827876A4
(en)
|
2012-03-22 |
2015-10-28 |
Alios Biopharma Inc |
PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
EP2854813B1
(en)
*
|
2012-05-31 |
2018-07-25 |
Bio-lab Ltd. |
Pyrazolotriazolyl nucleoside analogues and oligonucleotides comprising them
|
US9555036B2
(en)
|
2012-08-24 |
2017-01-31 |
Glaxosmithkline Llc |
Pyrazolopyrimidine compounds
|
ES2671478T3
(es)
|
2012-08-31 |
2018-06-06 |
Novartis Ag |
Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
MX2015005500A
(es)
*
|
2012-10-29 |
2016-02-09 |
Cocrystal Pharma Inc |
Nucleotidos de pirimidina y sus profarmacos de monofosfato para el tratamiento de infecciones virales y cancer.
|
WO2014074883A1
(en)
*
|
2012-11-08 |
2014-05-15 |
Lyndor Biosciences L.L.C. |
Novel synthesis of ld101
|
KR20150085081A
(ko)
|
2012-11-20 |
2015-07-22 |
글락소스미스클라인 엘엘씨 |
신규 화합물
|
EA028480B1
(ru)
|
2012-11-20 |
2017-11-30 |
ГЛАКСОСМИТКЛАЙН ЭлЭлСи |
Новые соединения
|
CN104780924B
(zh)
*
|
2012-11-20 |
2016-09-14 |
葛兰素史克有限责任公司 |
干扰素诱导剂化合物
|
EP3202403A1
(en)
|
2013-01-16 |
2017-08-09 |
Signal Pharmaceuticals, LLC |
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
|
WO2014121418A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
WO2014121417A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
US9447132B2
(en)
|
2013-04-12 |
2016-09-20 |
Achillion Pharmaceuticals, Inc. |
Highly active nucleoside derivative for the treatment of HCV
|
CN105392499B
(zh)
|
2013-04-17 |
2018-07-24 |
西格诺药品有限公司 |
用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
|
WO2014172430A1
(en)
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
|
US9505764B2
(en)
|
2013-04-17 |
2016-11-29 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
SG10201708111YA
(en)
|
2013-04-17 |
2017-11-29 |
Signal Pharm Llc |
Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
|
KR102271344B1
(ko)
|
2013-04-17 |
2021-07-01 |
시그날 파마소티칼 엘엘씨 |
디하이드로피라지노-피라진을 사용한 암의 치료
|
TWI654979B
(zh)
|
2013-04-17 |
2019-04-01 |
美商標誌製藥公司 |
使用tor激酶抑制劑組合療法以治療癌症之方法
|
KR102459285B1
(ko)
|
2013-04-17 |
2022-10-27 |
시그날 파마소티칼 엘엘씨 |
1-에틸-7-(2-메틸-6-(1H-1,2,4-트리아졸-3-일)피리딘-3-일)-3,4-디하이드로피라지노[2,3-b]피라진-2(1H)-온에 관한 약학 제제, 제조방법, 고체 형태 및 사용 방법
|
MX2015015880A
(es)
|
2013-05-29 |
2016-05-31 |
Signal Pharm Llc |
Composiciones farmaceuticas de 7-(6-(2-hidroxipropan-2-il)piridin- 3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b]pi razin-2(1h)-ona, una forma solida del mismo y metodos de su uso.
|
US10149859B2
(en)
|
2013-09-11 |
2018-12-11 |
Emory University |
Nucleotide and nucleoside therapeutic compositions and uses related thereto
|
JP2017512183A
(ja)
|
2014-02-13 |
2017-05-18 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
プロドラッグ化合物およびそれらの使用
|
US9512129B2
(en)
|
2014-04-16 |
2016-12-06 |
Signal Pharmaceuticals, Llc |
Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
EP3131552B1
(en)
|
2014-04-16 |
2020-07-15 |
Signal Pharmaceuticals, LLC |
Methods for treating cancer using tor kinase inhibitor combination therapy
|
US9718824B2
(en)
|
2014-04-16 |
2017-08-01 |
Signal Pharmaceuticals, Llc |
Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
|
WO2015191677A1
(en)
|
2014-06-11 |
2015-12-17 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
|
JP2017520545A
(ja)
|
2014-07-02 |
2017-07-27 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
プロドラッグ化合物およびそれらの使用
|
NZ629796A
(en)
|
2014-07-14 |
2015-12-24 |
Signal Pharm Llc |
Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
|
EA201790189A1
(ru)
|
2014-07-14 |
2017-11-30 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
|
TWI767201B
(zh)
|
2014-10-29 |
2022-06-11 |
美商基利科學股份有限公司 |
絲狀病毒科病毒感染之治療
|
UA122332C2
(uk)
|
2015-02-27 |
2020-10-26 |
Інсайт Корпорейшн |
Солі інгібітора pi3k і способи їх отримання
|
CA2978085C
(en)
|
2015-03-06 |
2023-01-17 |
Atea Pharmaceuticals, Inc. |
.beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
|
US10087209B2
(en)
|
2015-04-28 |
2018-10-02 |
Ku Leuven Research & Development |
Antiviral compounds, a process for their preparation, and their use for treating viral infections
|
WO2016183060A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
US9988401B2
(en)
|
2015-05-11 |
2018-06-05 |
Incyte Corporation |
Crystalline forms of a PI3K inhibitor
|
DK3349758T3
(da)
|
2015-09-16 |
2022-06-13 |
Gilead Sciences Inc |
Fremgangsmåder til behandling af arenaviridae-virusinfektioner
|
US10202412B2
(en)
|
2016-07-08 |
2019-02-12 |
Atea Pharmaceuticals, Inc. |
β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
|
CN116036114A
(zh)
|
2016-09-07 |
2023-05-02 |
阿堤亚制药公司 |
用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸
|
US9975915B1
(en)
|
2016-11-11 |
2018-05-22 |
The Queen's University Of Belfast |
Crystalline forms of nicotinoyl ribosides, modified derivatives thereof, and phosphorylated analogs thereof, and methods of preparation thereof
|
US11071747B2
(en)
|
2016-11-29 |
2021-07-27 |
University Of Iowa Research Foundation |
Use of NAD precursors for breast enhancement
|
JP7136795B2
(ja)
|
2016-11-29 |
2022-09-13 |
ユニバーシティー オブ アイオワ リサーチ ファウンデーション |
母体の健康および/または子の健康を向上させるためのnad前駆体の使用
|
JP7066728B2
(ja)
|
2017-02-01 |
2022-05-13 |
アテア ファーマシューティカルズ, インコーポレイテッド |
C型肝炎ウイルスの治療のためのヌクレオチドヘミ硫酸塩
|
WO2018169946A1
(en)
|
2017-03-14 |
2018-09-20 |
Gilead Sciences, Inc. |
Methods of treating feline coronavirus infections
|
ES2938859T3
(es)
|
2017-05-01 |
2023-04-17 |
Gilead Sciences Inc |
Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato
|
CN110996955A
(zh)
|
2017-06-22 |
2020-04-10 |
细胞基因公司 |
以乙型肝炎病毒感染为特征的肝细胞癌的治疗
|
CN111093627B
(zh)
|
2017-07-11 |
2024-03-08 |
吉利德科学公司 |
用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
|
EP3737676B1
(en)
|
2018-01-09 |
2024-03-06 |
Ligand Pharmaceuticals, Inc. |
Acetal compounds and therapeutic uses thereof
|
WO2019143977A1
(en)
*
|
2018-01-18 |
2019-07-25 |
Array Biopharma Inc. |
Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
|
CN108484705B
(zh)
*
|
2018-01-25 |
2020-09-01 |
中国医学科学院医药生物技术研究所 |
一种西奈芬净类似物及其制备方法
|
EP3773753A4
(en)
|
2018-04-10 |
2021-12-22 |
ATEA Pharmaceuticals, Inc. |
TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
|
CN109897081A
(zh)
*
|
2019-04-01 |
2019-06-18 |
大连大学 |
一种5-Br-2’,3’,5’-O-三乙酰基尿苷合成方法
|
CN109776638A
(zh)
*
|
2019-04-01 |
2019-05-21 |
大连大学 |
一种5-Br-3’,5’-O-二乙酰基-2’-脱氧尿苷合成方法
|
US11660307B2
(en)
|
2020-01-27 |
2023-05-30 |
Gilead Sciences, Inc. |
Methods for treating SARS CoV-2 infections
|
US10874687B1
(en)
|
2020-02-27 |
2020-12-29 |
Atea Pharmaceuticals, Inc. |
Highly active compounds against COVID-19
|
TW202309061A
(zh)
|
2020-03-12 |
2023-03-01 |
美商基利科學股份有限公司 |
1’-氰基核苷之製備方法
|
AU2021251689B2
(en)
|
2020-04-06 |
2024-06-13 |
Gilead Sciences, Inc. |
Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
|
CN111995649A
(zh)
*
|
2020-04-09 |
2020-11-27 |
瀚海新拓(杭州)生物医药有限公司 |
一种蝶啶酮核苷酸类似物及其药物组合物、制备方法和医药用途
|
KR20230018473A
(ko)
|
2020-05-29 |
2023-02-07 |
길리애드 사이언시즈, 인코포레이티드 |
렘데시비르 치료 방법
|
MX2022016405A
(es)
|
2020-06-24 |
2023-01-30 |
Gilead Sciences Inc |
Análogos de nucleósido de 1¿-ciano y usos de estos.
|
LT4204421T
(lt)
|
2020-08-27 |
2024-06-25 |
Gilead Sciences, Inc. |
Virusinių infekcijų gydymui skirti junginiai ir būdai
|
CN116367841A
(zh)
*
|
2020-10-02 |
2023-06-30 |
圣诺制药公司 |
用于治疗病毒性疾病的含有核苷的siRNA
|
CN112851719A
(zh)
*
|
2021-03-10 |
2021-05-28 |
康化(上海)新药研发有限公司 |
一种贾斯帕霉素的合成方法
|
KR20240050362A
(ko)
|
2021-08-20 |
2024-04-18 |
시오노기 앤드 컴파니, 리미티드 |
바이러스 증식 억제 작용을 갖는 뉴클레오사이드 유도체 및 그들의 프로드러그
|
IL313141A
(en)
*
|
2021-12-03 |
2024-07-01 |
Quralis Corp |
Antisense oligonucleotides exchange linkage with altered backbone chemistry
|
WO2023167944A1
(en)
|
2022-03-02 |
2023-09-07 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
CN117645636B
(zh)
*
|
2024-01-30 |
2024-04-16 |
深圳赛陆医疗科技有限公司 |
一种腺嘌呤叠氮中间体的制备方法
|